We provide innovative medical propellants to the world’s biggest pharmaceutical companies. All of our products are produced to the most demanding industry standards at our dedicated facilities. Find out more about our global community.
Menu
Search
Search
Zephex® 152a: reducing the carbon footprint of asthma inhalers
Zephex® 152a: reducing the carbon footprint of asthma inhalers
Find out more
Zephex® 152a
Zephex® 152a will reduce the carbon footprint by 90% compared to current metered dose inhalers. Our low GWP medical propellant is a commitment to both end users and our environment.
From the Newsroom
Koura: Rising to the Challenge
The Chemical Industries Association has launched part 3 of their ‘COVID-19 Response’ series, which looks at the work being done across the industry to help
Read more
Koura opens world’s first HFA 152a medical propellant production facility
• New HFA 152a production facility will produce low global warming potential (GWP) propellants for pressurised metered dose inhalers (pMDIs). • The new propellant will
Read more
A sustainable solution for inhalers
Koura has developed a new medical propellant that makes managing asthma both environmentally and user-friendly by Dr Stuart Corr, Techno-commercial Director Asthma is an extremely
Read more
Medical Propellants – a journey from CFC to HFA 152a
We interviewed Dr. Tim Noakes, Koura’s Technical Associate, who has had a fundamental role in the creation of the HFA medical propellant business for ICI
Read moreUpcoming Events
- End-to-end Sustainability Forum 20-22 September
- DDL 2021 8-10 December Register